Effect of KW-8232, a Novel Anti-osteoporotic Agent, on Bone Loss in Sciatic Neurectomized Rats

Access this Article

Author(s)

    • Uchii Masako UCHII Masako
    • General Pharmacology, Drug Discovery Research Laboratories, Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co., Ltd.
    • KOSAKA Nobuo
    • General Pharmacology, Drug Discovery Research Laboratories, Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co., Ltd.

Abstract

The purpose of this study was to evaluate the effects of 3-[bis(4-hydrozuphenyl)methyl]-2-[4-(2-chlorophenyl)-piperazin-1-ylcarbonyl]-1-(2-dimethylaminoethyl) indole methanesulfonate (KW-8232), a novel anti-osteoporotic agent, on bone loss in neurectomized rats. We also investigated the effect of KW-8232 on bone resorption in this animal model. Male Sprague-Dawley rats underwent unilateral hind-limb immobilization by sciatic neurectomy. KW-8232 (3, 10 and 30 mg/kg, p.o.) was effective in inhibiting femoral bone loss. KW-8232 decreased urinary pyridinoline and deoxypyridinoline excretion. These results indicate that KW-8232 effectively prevents the bone loss due to immobilization.

Journal

  • The Japanese Journal of Pharmacology

    The Japanese Journal of Pharmacology 78(2), 241-243, 1998-10-01

    The Japanese Pharmacological Society

References:  10

Codes

  • NII Article ID (NAID)
    10008680946
  • NII NACSIS-CAT ID (NCID)
    AA00691188
  • Text Lang
    ENG
  • Article Type
    ART
  • ISSN
    00215198
  • NDL Article ID
    4591524
  • NDL Source Classification
    ZS51(科学技術--薬学)
  • NDL Call No.
    Z53-D199
  • Data Source
    CJP  NDL  J-STAGE 
Page Top